Evidence map›Paper›PMID 40506802›Full record

ArticleBritish journal of haematology2025

Impact of CHEK2 germline variants on haematological malignancy risk and outcomes of allogeneic HSCT.

Atte K Lahtinen, Maarja Karu, Jessica R Koski, Jarmo Ritari, Kati Hyvärinen, Satu Koskela, Julia Nihtilä, Jukka Partanen, Kim Vettenranta, Minna Koskenvuo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Atte K LahtinenApplied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-2019-897X
Maarja KaruDepartment of Hematology and Oncology, Tallinn Children's Hospital, Tallinn, Estonia.ORCID https://orcid.org/0009-0005-5099-8635
Jessica R KoskiApplied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Jarmo RitariResearch and Development, Finnish Red Cross Blood Service, Helsinki, Finland.
Kati HyvärinenResearch and Development, Finnish Red Cross Blood Service, Helsinki, Finland.
Satu KoskelaResearch and Development, Finnish Red Cross Blood Service, Helsinki, Finland.
Julia NihtiläResearch and Development, Finnish Red Cross Blood Service, Helsinki, Finland.
Jukka PartanenResearch and Development, Finnish Red Cross Blood Service, Helsinki, Finland.
Kim VettenrantaNew Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Minna KoskenvuoNew Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Riitta NiittyvuopioDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
Urpu SalmenniemiDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland.
Maija Itälä-RemesDepartment of Clinical Hematology and Stem Cell Transplant Unit, Turku University Hospital, University of Turku, Turku, Finland.
Kirsi JahnukainenNew Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Outi KilpivaaraApplied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0001-8467-2100
Ulla Wartiovaara-KauttoApplied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Funding

Ane and Signe Gyllenberg FoundationBiomedicum Helsinki FoundationCancer Foundation FinlandFinnish Association of HematologyFinnish Funding Agency for Technology and InnovationFinnish Medical FoundationFinnish Special Governmental Subsidy for Health Sciences, Research, and TrainingFoundation for Pediatric ResearchHelsinki University Hospital Comprehensive Cancer Research FundingiCAN Digital Precision Cancer MedicineIda Montin FoundationJalmari and Rauha Ahokas FoundationResearch Council of Finland #349760Sigrid Jusélius FoundationSwedish Childhood Cancer Foundation KP2020-0012The Birgitta and Carl-Axel Rydbeck's Research Grant for Paediatric Research 2020-00335The Birgitta and Carl-Axel Rydbeck's Research Grant for Paediatric Research 2021-00079The Birgitta and Carl-Axel Rydbeck's Research Grant for Paediatric Research 2023-00380Väre Foundation for Pediatric Cancer Research
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute leukaemiaallogeneic haematopoietic stem cell transplantationCHEK2germlinehaematological malignancy

Identifiers

PMID40506802
PMCPMC12378959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.